A New Obesity Pill May Burn Fat Without Suppressing Appetite

A new experimental obesity pill called SANA, developed by Eolo Pharma, shows promise in promoting weight loss by a novel mechanism that burns fat through creatine-dependent thermogenesis rather than suppressing appetite. Unlike popular drugs such as Ozempic and Wegovy, which reduce food intake by enhancing feelings of fullness and slowing gastric emptying, SANA activates a pathway in fat cells that generates heat and energy by breaking down creatine. This approach led to statistically significant weight loss of about 3 percent in obese participants over two weeks, comparable to the effects of GLP-1 drugs, but without reported decreases in appetite or satiety. The Phase I trial involved healthy-weight and obese participants who received varying doses of SANA or placebo. The drug was safe and well-tolerated with no serious side effects. Participants remained on high-carbohydrate diets during the study, yet those on the highest dose of SANA lost weight while maintaining appetite. Preclinical studies in mice showed that SANA not only